MedPath

The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

Not Applicable
Conditions
hemodialysis patient
Registration Number
JPRN-UMIN000007234
Lead Sponsor
Tokyo Women's Medical University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
6
Inclusion Criteria

Not provided

Exclusion Criteria

1) History of hypersensitivity, allergy or serious adverse drug event caused by oseltamivir phosphate, zanamivir hydrate, peramivir hydrate or raninanivir. 2)Patient with contraindications of 1) drugs. 3)Hepatic disorder. 4) Women who are pregnant or suspected to be pregnant and women who are breast-feeding. 5) Any other patients whose condition is inappropriate for the evaluation of this clinical study as judged by the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the appropriate usage/dosage of peramivir.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath